UPDATE: ABBV-969 Shows Very Promising rFPS in mCRPC

ABBV-969 is a dual-target antibody-drug conjugate targeting PSMA and STEAP1,data about its radiographic progression-free survival data have just been released, confirming a median rPFS of approximately 15 months in heavily pretreated metastatic castration-resistant prostate cancer.
The study demonstrates a signal far exceeding the 4- to 5-month rPFS historically seen with cabazitaxel in the same patient population. The bispecific ADC delivers a topoisomerase inhibitor payload rather than a taxane, avoiding the peripheral neuropathy that commonly limits taxane-based chemotherapy after prior exposure. Tumor heterogeneity in late-stage prostate cancer means some lesions express high PSMA while others express primarily STEAP1, and binding either antigen allows the conjugate to reach a broader range of tumor cells within the same patient, potentially delaying resistance from antigen-low clones. The most prominent adverse event remains anemia, with grade 3 events occurring in over 40 percent of patients, though dose modifications and transfusions have enabled most participants to continue treatment without discontinuation. Median treatment duration of about 296 days supports sustained benefit and manageable tolerability. This rPFS signal positions ABBV-969 as a promising non-taxane option for patients who have exhausted prior therapies including androgen receptor pathway inhibitors and taxane chemotherapy.

Source.